The Evaluate Vantage PD(L)anner – March 2022 provides news, insights and analysis on the PD-(L)1 antibody landscape. Among other issues, we focus on potential pricing changes, provide an update on what’s happening in China and other markets, and share our views on the results of recent studies. To access your complimentary copy of this special […]
Share:
The Evaluate Vantage PD(L)anner – March 2022 provides news, insights and analysis on the PD-(L)1 antibody landscape. Among other issues, we focus on potential pricing changes, provide an update on what’s happening in China and other markets, and share our views on the results of recent studies.
To access your complimentary copy of this special report, please fill in this form.
By 2032, the global pharmaceutical market is forecast to reach almost $1.9tn. Inside the innovations, dealmaking, and portfolio strategies transforming the global biopharma pipeline.
